A comprehensive view of MiMedx Group Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.
MiMedx Group enters an agreement with TELA Bio to gain exclusive rights to manufacturing and supply agreement with Regenity Biosciences; the deal allows MiMedx to add xenograft products to its portfolio of advanced wound care and surgical solutions
Published:
March 20, 2024
by GlobeNewswire
|
Ask us about our Bioeconomy market view